Source: Annual Congress 2013 –Antibiotics, resistance and vaccines
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
P. Ekren, Z. N. Töreyin, A. çeltik, H. Pullukçu, A. Gürgün, H. Uluer, F. Bacakoglu, S. S. Aydemir, A. Sayiner (Izmir, Turkey). Colistin therapy for nosocomial pneumonia and nephrotoxicity. Eur Respir J 2013; 42: Suppl. 57, 2749

Member's Comments

No comment yet.

Related content which might interest you: Empirical treatment of community-acquired pneumonia after outpatient beta-lactam therapy Source: International Congress 2016 – Community-acquired pneumonia: from prevention to treatment Year: 2016 Comparison of ampicillin-sulbactam/macrolide dual therapy versus fluoroquinolone monotherapy in hospitalized patients with community-acquired pneumonia Source: International Congress 2015 – Clinical issues in CAP: microbiological and radiological determinants Year: 2015 Multidrug resistant acinetobacter baumanii pneumonia: Mortality analysis and comparison of intravenous versus aerosolized therapy Source: International Congress 2014 – Antibiotics, antifungals and other therapeutic options Year: 2014 Can the broad-spectrum antibiotics improve the prognoses of high-risk nursing- and healthcare-associated pneumonia? Source: International Congress 2014 – Epidemiology, scores and outcomes of respiratory infections Year: 2014 Treatment of nosocomial pneumonia with piperacillin-tazobactam Source: Eur Respir J 2007; 30: Suppl. 51, 53s Year: 2007 Benefits of co-administration of macrolides and glucocorticosteroids in the treatment of severe community acquired pneumonia Source: International Congress 2016 – Community-acquired pneumonia: update on prognostic factors and therapeutic strategies Year: 2016 Multidrug-resistant pathogens in hospitalized patients coming from the community with pneumonia Source: Annual Congress 2013 –Recent developments in pneumonia Year: 2013 Community-acquired pneumonia due to multidrug and non-multidrug resistant pseudomonas aeruginosa Source: International Congress 2016 – Community-acquired pneumonia: from prevention to treatment Year: 2016 Survival benefit of beta-lactam plus macrolide combined therapy versus beta-lactam plus quinolones in hospitalized community-acquired pneumonia Source: International Congress 2016 – Community-acquired pneumonia: update on prognostic factors and therapeutic strategies Year: 2016 Development of an antibody therapy for the treatment of pneumonia Source: International Congress 2016 – Microbiological issues and translational research in respiratory infections Year: 2016 Non CF bronchiectasis: The effect of inhaled antibiotics (tobramycin and colistin) in patients with pseudomonas aeruginosa Source: International Congress 2014 – Interventions and other therapeutic approaches in respiratory infections Year: 2014 Health care-associated pneumonia and community-acquired pneumonia: A single-center experience Source: International Congress 2015 – CAP: prognostic factors in frail patients Year: 2015 Aminoglycoside use for pseudomonas aeruginosa in bronchiectasis Source: International Congress 2014 – Antibiotics, antifungals and other therapeutic options Year: 2014 Predictors of treatment failure in patients with bacteremic pneumococcal community-acquired pneumonia Source: Annual Congress 2013 –Pneumonia and sepsis Year: 2013 Dynamic of adherence to guidelines for antibiotic therapy of community-aquired pneumonia (CAP) Source: Annual Congress 2013 –Antibiotics, resistance and vaccines Year: 2013 Ventilator-associated pneumonia due to colistin susceptible-only microorganisms Source: Eur Respir J 2007; 30: 307-313 Year: 2007 Modification of empirical antibiotic therapy in community acquired pneumonia Source: International Congress 2014 – Different interesting issues in respiratory infections: 2 Year: 2014 Pseudomonas aeruginosa pneumonia in the community Source: International Congress 2014 – Different interesting issues in respiratory infections: 2 Year: 2014 New antibiotics for VAP Source: Eur Respir Mon 2011; 53: 48-53 Year: 2011 Beta lactam plus macrolide antibiotic combination therapy reduces the mortality of community-acquired pneumococcal pneumonia more than beta lactam antibiotics alone Source: International Congress 2014 – Antibiotics, antifungals and other therapeutic options Year: 2014